AstraZeneca, for the first time, acknowledges the potential side effects of its Covid-19 vaccine, Covishield, in a recent legal disclosure. The admission comes amidst a class-action lawsuit alleging severe complications and even fatalities associated with the vaccine.

In the legal battle, AstraZeneca admits to the rare occurrence of Thrombosis with Thrombocytopenia Syndrome (TTS), characterized by blood clots and low platelet counts, as a consequence of its vaccine.

The lawsuit, spearheaded by individuals like Jamie Scott, highlights the devastating impact of TTS, with cases of permanent brain injury and other severe outcomes following vaccination.

AstraZeneca’s concession in court documents submitted to the UK High Court signifies a significant milestone in the ongoing legal dispute, shedding light on the potential risks associated with the vaccine.

Despite the acknowledgement of rare side effects, AstraZeneca maintains its stance on vaccine efficacy and disputes claims of widespread defects.

The discontinuation of the AstraZeneca-Oxford vaccine in the UK due to safety concerns underscores the gravity of the situation, despite its proven effectiveness in combating the pandemic.

While independent studies affirm the vaccine’s efficacy, the emergence of rare side effects has prompted regulatory scrutiny and legal action worldwide.

As legal proceedings unfold, affected individuals and their families seek recourse and acknowledgment of vaccine-induced injuries from AstraZeneca.

The admission by AstraZeneca, albeit under legal pressure, underscores the importance of transparency and accountability in vaccine development and distribution.

By : Kruthiga V S

—-

#healthcare #covid19 #vaccinesafety #AstraZeneca #Covishield #legalbattle #publichealth #transparency #riskmanagement #pandemicresponse #regulatoryscrutiny #accountability #vaccineinjury #UKHighCourt #healthcrisis